Bilaketaren emaitzak - Mahmoud Al‐Hawary
- Erakusten 1 - 2 emaitzak -- 2
-
1
Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma nork Petros Grivas, Stephanie Daignault, Scott T. Tagawa, David M. Nanus, Walter M. Stadler, Robert Dreicer, Manish Kohli, Daniel P. Petrylak, David J. Vaughn, Kathryn Bylow, Steven Wong, Joseph L. Sottnik, Evan T. Keller, Mahmoud Al‐Hawary, David C. Smith, Maha Hussain
Argitaratua 2013Artigo -
2
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma nork Maha Hussain, Stephanie Daignault, Neeraj Agarwal, Petros Grivas, Arlene O. Siefker‐Radtke, Igor Puzanov, Gary R. MacVicar, Ellis Levine, Sandy Srinivas, Przemyslaw Twardowski, Mario A. Eisenberger, David I. Quinn, Ulka N. Vaishampayan, Evan Y. Yu, Scott J. Dawsey, Kathleen C. Day, Mark L. Day, Mahmoud Al‐Hawary, David C. Smith
Argitaratua 2014Artigo
Bilaketa egiteko lanabesak:
Antzeko gaiak
Cancer
Chemotherapy
Clinical endpoint
Internal medicine
Medicine
Oncology
Progression-free survival
Randomized controlled trial
Surgery
Adverse effect
Alternative medicine
Bevacizumab
Cetuximab
Colorectal cancer
Common Terminology Criteria for Adverse Events
Gastroenterology
Gemcitabine
Mucositis
Pathology
Phases of clinical research
Placebo
Sunitinib
Urology